Source-grounded facts extracted from SUPERNUS PHARMACEUTICALS, INC.'s SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
SUPERNUS PHARMACEUTICALS, INC. incurred debt of approximately $33.4 million with Equiniti Trust Company, LLC.
“On May 17, 2026 (the “Notice Date”), pursuant to the Contingent Value Right Agreement (the “CVR Agreement”) entered into as of July 30, 2025, by and between Supernus Pharmaceuticals, Inc., a Delaware corporation (the “Company”) and Equiniti Trust Company, LLC, a New York limited liability trust company, as Rights Agent, the Company notified the Rights Agent that Milestone 1, as defined in the CVR Agreement, was achieved on March 18, 2026.”
Earnings Releases
SUPERNUS PHARMACEUTICALS, INC. reported the first quarter ended March 31, 2026 results: revenue $207.7 million. Guidance reaffirmed.
“Supernus Announces First Quarter 2026 Financial Results • Total revenues were $207.7 million in the first quarter 2026”
Earnings Releases
SUPERNUS PHARMACEUTICALS, INC. reported financial results for first quarter of 2026.
“On April 22, 2026, Supernus Pharmaceuticals, Inc. issued a press release announcing that it will report its business results for the first quarter of 2026 after the market closes on Tuesday, May 5, 2026.”
Material Agreements
SUPERNUS PHARMACEUTICALS, INC. entered into Asset Purchase Agreement with Navitor Pharmaceuticals, Inc., Navitor Pharmaceuticals, LLC valued at up to $350 million (effective 2026-04-01).
“On April 1, 2026, Supernus Pharmaceuticals, Inc. (the “Company”) entered into an Asset Purchase Agreement (the “Agreement”), together with related ancillary transaction documents, with Navitor Pharmaceuticals, Inc., a Delaware corporation (“Navitor”), Navitor Pharmaceuticals, LLC, a Delaware limited liability company (“Navitor Parent,” and, together with Navitor, the “Sellers”).”
Material Agreements
SUPERNUS PHARMACEUTICALS, INC. amended First Amendment with Reich Consulting Group, Inc. as the Securityholder Representative (effective 2026-01-22).
“On January 22, 2026, Supernus Pharmaceuticals, Inc. (the “Company”) entered into a First Amendment (the “Amendment”) to the Agreement and Plan of Merger dated September 12, 2018 (the “Merger Agreement”), with Reich Consulting Group, Inc. as the Securityholder Representative.”
M&A Transactions
SUPERNUS PHARMACEUTICALS, INC. completed an acquisition involving Sage Therapeutics, Inc. for approximately $561 million (closed 2025-07-31).
“which is calculated and payable in accordance with the CVR Agreement. The aggregate consideration to be paid by Purchaser to complete the Offer and the Merger is approximately $561 million (exclusive of amounts that may be payable pursuant to the CVRs), without giving effect to related transaction fees and expenses. The foregoing description of the Merger”
Earnings Releases
SUPERNUS PHARMACEUTICALS, INC. updated its the first quarter of 2024 guidance (reaffirmed).
“On May 8, 2024, Supernus Pharmaceuticals, Inc. ("Supernus" or the "Company") issued a press release regarding its financial results for the first quarter ended March 31, 2024.”
John M. Siebert retired as Director at SUPERNUS PHARMACEUTICALS, INC..
“On April 22, 2024, John M. Siebert, Ph.D. informed Supernus Pharmaceuticals, Inc. (the “Company”) that he has decided to retire from the Company's Board of Directors (the "Board"), effective at the Company's Annual Meeting of Stockholders in June 2024”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.